Contributions
Abstract: P381
Type: Poster
Abstract Category: Clinical aspects of MS - Neuro-ophthalmology
Studies using cell-based immunoassays have demonstrated the presence of antibodies (Abs) targeting aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG) in some patients with optic neuritis (ON) not related to multiple sclerosis.
Objective: To compare the characteristics of ON in two populations, AQP4 positive and MOG positive.
Methods: We retrospectively reviewed the medical records of all the patients admitted in our institution with ON associated with AQP4 or MOG Abs. Demographic characteristics, clinical neurologic and ophthalmic findings, cerebrospinal fluid (CSF), brain and orbital MRI and OCT features, treatments, and course of disease were studied.
Results: 24 AQP4+ patients (leading to 62 ON episodes; 87.5% women) and 12 MOG+ patients (28 ON; 58.3%) were analyzed. We found no significant differences concerning age of onset, annual rate of inflammatory events, and time before relapses. Patients with MOG Abs had significantly more bilateral ON (p=0.0059) and better initial visual acuity (p=0.033), mean deviation of the visual field (p=0.009), and final visual acuity (p=0.046). Area postrema syndrome, oligoclonal bands in CSF and posterior visual pathway involvement on MRI were not observed in our MOG population.
Conclusion: Our study confirm that ON with MOG-Abs have distinctive features than AQP4+ patients, in particular better visual prognosis, but the risk of relapse isn"t different.
Disclosure: Karen Lecouturier: Nothing to disclose
Abstract: P381
Type: Poster
Abstract Category: Clinical aspects of MS - Neuro-ophthalmology
Studies using cell-based immunoassays have demonstrated the presence of antibodies (Abs) targeting aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG) in some patients with optic neuritis (ON) not related to multiple sclerosis.
Objective: To compare the characteristics of ON in two populations, AQP4 positive and MOG positive.
Methods: We retrospectively reviewed the medical records of all the patients admitted in our institution with ON associated with AQP4 or MOG Abs. Demographic characteristics, clinical neurologic and ophthalmic findings, cerebrospinal fluid (CSF), brain and orbital MRI and OCT features, treatments, and course of disease were studied.
Results: 24 AQP4+ patients (leading to 62 ON episodes; 87.5% women) and 12 MOG+ patients (28 ON; 58.3%) were analyzed. We found no significant differences concerning age of onset, annual rate of inflammatory events, and time before relapses. Patients with MOG Abs had significantly more bilateral ON (p=0.0059) and better initial visual acuity (p=0.033), mean deviation of the visual field (p=0.009), and final visual acuity (p=0.046). Area postrema syndrome, oligoclonal bands in CSF and posterior visual pathway involvement on MRI were not observed in our MOG population.
Conclusion: Our study confirm that ON with MOG-Abs have distinctive features than AQP4+ patients, in particular better visual prognosis, but the risk of relapse isn"t different.
Disclosure: Karen Lecouturier: Nothing to disclose